Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Burger

Showing results (51-60 of 337) with videos related to

Pageof 34
Sort By:
AIDS (London, England)|July 11, 2003
Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacyCharles J L la Porte, Jan-Christian Wasmuth, Katrin Schneider, et al.
Therapeutic Drug Monitoring|April 23, 2019
Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIVHylke Waalewijn, Anna Turkova, Natella Rakhmanina, et al.
Antiviral Therapy|January 25, 2006
Role of the inhibitory quotient in HIV therapyJolando G M Hoefnagel, Peter P Koopmans, David M Burger, et al.
Antiviral Therapy|May 12, 2004
Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR)Jan-Christian Wasmuth, Charles J L la Porte, Katrin Schneider, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2005
Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studiesEva Muro, Jacqueline A H Droste, Hadewych Ter Hofstede, et al.
AIDS (London, England)|December 20, 2023
The impact of obesity on doravirine exposure in people with HIVLeena Zino, Lianne P M van Bussel, Rick Greupink, et al.
Antiviral Therapy|March 31, 2011
Interaction between antiretroviral drugs and acenocoumarolMarieke E B Welzen, Guido E L van den Berk, Raph L Hamers, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|February 19, 2019
Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MSMinou van Seyen, Marga J A de Graaff Teulen, Nielka P van Erp, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 31, 2006
Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy womenRafaëlla F A L'homme, Tim Dijkema, Andre J A M van der Ven, et al.
Cancer Chemotherapy and Pharmacology|February 21, 2020
The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patientsGuillemette E Benoist, Inge M van Oort, David M Burger, et al.
Pageof 34

Showing results (51-60 of 337) with videos related to

Sort By:
Pageof 34
AIDS (London, England)|July 11, 2003
Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacyCharles J L la Porte, Jan-Christian Wasmuth, Katrin Schneider, et al.
Therapeutic Drug Monitoring|April 23, 2019
Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIVHylke Waalewijn, Anna Turkova, Natella Rakhmanina, et al.
Antiviral Therapy|January 25, 2006
Role of the inhibitory quotient in HIV therapyJolando G M Hoefnagel, Peter P Koopmans, David M Burger, et al.
Antiviral Therapy|May 12, 2004
Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR)Jan-Christian Wasmuth, Charles J L la Porte, Katrin Schneider, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|July 13, 2005
Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studiesEva Muro, Jacqueline A H Droste, Hadewych Ter Hofstede, et al.
AIDS (London, England)|December 20, 2023
The impact of obesity on doravirine exposure in people with HIVLeena Zino, Lianne P M van Bussel, Rick Greupink, et al.
Antiviral Therapy|March 31, 2011
Interaction between antiretroviral drugs and acenocoumarolMarieke E B Welzen, Guido E L van den Berk, Raph L Hamers, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences|February 19, 2019
Quantification of second generation direct-acting antivirals daclatasvir, elbasvir, grazoprevir, ledipasvir, simeprevir, sofosbuvir and velpatasvir in human plasma by UPLC-MS/MSMinou van Seyen, Marga J A de Graaff Teulen, Nielka P van Erp, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 31, 2006
Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy womenRafaëlla F A L'homme, Tim Dijkema, Andre J A M van der Ven, et al.
Cancer Chemotherapy and Pharmacology|February 21, 2020
The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patientsGuillemette E Benoist, Inge M van Oort, David M Burger, et al.
Pageof 34